RLAY (Relay Therapeutics) Non Operating Income: $-0.19 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLAY Relay Therapeutics Inc RLAY
42 GF Score
Price $19.46
GF Value $3.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Relay Therapeutics Non Operating Income?

Relay Therapeutics RLAY -5.40% 42 Non Operating Income is $-0.19 Mil as of Jun. 2026. GuruFocus rates RLAY with a GF Score™ of 42/100 and a GF Value™ of $3.45 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Relay Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.19 Mil.

Relay Therapeutics Non Operating Income Related Terms

Relay Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Relay Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relay Therapeutics Non Operating Income Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial -137.70 11.66 6.40 13.22 -0.78

Relay Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.17 0.03 -0.05 0.00
RLAY
42GF Score
Relay Therapeutics Inc RLAY
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relay Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-0.19 Mil mean?
Relay Therapeutics (RLAY) has a Non Operating Income of $-0.19 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Relay Therapeutics and its competitors.
Is Relay Therapeutics' Non Operating Income too high?
Relay Therapeutics' current Non Operating Income is $-0.19 Mil. Overall, Relay Therapeutics has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Non Operating Income compare to CELC and VKTX?
Relay Therapeutics' Non Operating Income of $-0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Relay Therapeutics and its competitors. Relay Therapeutics's current Non Operating Income is $-0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.45, compared to a current price of $19.46 — trading 464.1% above its estimated fair value. The current Non Operating Income is $-0.19 Mil. Relay Therapeutics' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Non Operating Income is $-0.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relay Therapeutics (RLAY) Overvalued in 2026?

Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued. The current stock price of $19.46 is trading 464.1% above its estimated GF Value™ of $3.45. GuruFocus considers Relay Therapeutics to be Significantly Overvalued.

Key valuation signals for RLAY:

  • Non Operating Income: $-0.19 Mil
  • GF Value™: $3.45 vs. price of $19.46 (464.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relay Therapeutics Business Description

Address 60 Hampshire Street, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
42GF Score

Get the complete analysis for RLAY

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.46
Price
$3.45
GF Value